Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study

A prospective, international phase 2 study of bortezomib retreatment in patients with relapsed multiple myeloma

(2013) Maria T. Petrucci et al.   BRITISH JOURNAL OF HAEMATOLOGY

Cdc42 regulates neutrophil migration via crosstalk between WASp, CD11b, and microtubules

(2012) S. Kumar et al.   BLOOD

Combination of bendamustine, lenalidomide, and dexamethasone (BLD) in patients with relapsed or refractory multiple myeloma is feasible and highly effective: results of phase 1/2 open-label, dose escalation study

(2012) S. Lentzsch et al.   BLOOD

Phase I/II trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myeloma

(2012) James R. Berenson et al.   BRITISH JOURNAL OF HAEMATOLOGY

Infection complications in an unselected cohort of patients with multiple myeloma treated with lenalidomide combinations

(2012) Tommaso Caravita et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Combined bendamustine, prednisone and bortezomib (BPV) in patients with relapsed or refractory multiple myeloma

(2012) Wolfram Pönisch et al.   JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY

Superiority of the Triple Combination of Bortezomib-Thalidomide-Dexamethasone Over the Dual Combination of Thalidomide-Dexamethasone in Patients With Multiple Myeloma Progressing or Relapsing After Autologous Transplantation: The MMVAR/IFM 2005-04 Randomized Phase III Trial From the Chronic Leukemia Working Party of the European Group for Blood and Marrow Transplantation

(2012) Laurent Garderet et al.   JOURNAL OF CLINICAL ONCOLOGY

Lenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma

(2012) Michel Attal et al.   NEW ENGLAND JOURNAL OF MEDICINE

Lenalidomide after Stem-Cell Transplantation for Multiple Myeloma

(2012) Philip L. McCarthy et al.   NEW ENGLAND JOURNAL OF MEDICINE

European Perspective on Multiple Myeloma Treatment Strategies: Update Following Recent Congresses

(2012) H. Ludwig et al.   ONCOLOGIST

The Future of Therapy for Relapsed/Refractory Multiple Myeloma: Emerging Agents and Novel Treatment Strategies

(2012) Philippe Moreau   SEMINARS IN HEMATOLOGY

Management Strategies for Relapsed/Refractory Multiple Myeloma: Current Clinical Perspectives

(2012) Andrzej Jakubowiak   SEMINARS IN HEMATOLOGY

Thalidomide, dexamethasone, Doxil and Velcade (ThaDD-V) followed by consolidation/maintenance therapy in patients with relapsed–refractory multiple myeloma

(2011) Massimo Offidani et al.   ANNALS OF HEMATOLOGY

Personalized therapy in multiple myeloma according to patient age and vulnerability: a report of the European Myeloma Network (EMN)

(2011) A. Palumbo et al.   BLOOD

Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study

(2011) Philippe Moreau et al.   LANCET ONCOLOGY

Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and ‘retreatment’ approaches in the era of novel agents

(2011) B Mohty et al.   LEUKEMIA

Management of treatment-emergent peripheral neuropathy in multiple myeloma

(2011) P G Richardson et al.   LEUKEMIA

Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: A multicenter international myeloma working group study

(2011) S K Kumar et al.   LEUKEMIA

Efficacy of bendamustine in relapsed/refractory myeloma patients: results from the French compassionate use program

(2011) G. Damaj et al.   LEUKEMIA & LYMPHOMA

Mechanism of Action: The Unique Pattern of Bendamustine-Induced Cytotoxicity

(2011) Lorenzo M. Leoni et al.   SEMINARS IN HEMATOLOGY

Bortezomib, doxorubicin, and dexamethasone combination therapy followed by thalidomide and dexamethasone consolidation as a salvage treatment for relapsed or refractory multiple myeloma: analysis of efficacy and safety

(2010) Sung Sook Lee et al.   ANNALS OF HEMATOLOGY

Emerging therapies for the treatment of relapsed or refractory multiple myeloma

(2010) Meletios A. Dimopoulos et al.   EUROPEAN JOURNAL OF HAEMATOLOGY

Bortezomib-Melphalan-Prednisone-Thalidomide Followed by Maintenance With Bortezomib-Thalidomide Compared With Bortezomib-Melphalan-Prednisone for Initial Treatment of Multiple Myeloma: A Randomized Controlled Trial

(2010) Antonio Palumbo et al.   JOURNAL OF CLINICAL ONCOLOGY

Cytogenetics of Childhood Acute Myeloid Leukemia: United Kingdom Medical Research Council Treatment Trials AML 10 and 12

(2010) Christine J. Harrison et al.   JOURNAL OF CLINICAL ONCOLOGY

Impact of high-risk cytogenetics and prior therapy on outcomes in patients with advanced relapsed or refractory multiple myeloma treated with lenalidomide plus dexaméthasone

(2010) H Avet-Loiseau et al.   LEUKEMIA

Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study

(2009) Yeo-Kyeoung Kim et al.   ANNALS OF HEMATOLOGY

Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure

(2008) M. Wang et al.   BLOOD

Defective homing is associated with altered Cdc42 activity in cells from patients with Fanconi anemia group A

(2008) X. Zhang et al.   BLOOD

Combined bendamustine, prednisolone and thalidomide for refractory or relapsed multiple myeloma after autologous stem-cell transplantation or conventional chemotherapy: results of a Phase I clinical trial

(2008) Wolfram Pönisch et al.   BRITISH JOURNAL OF HAEMATOLOGY

High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program

(2008) Joseph R. Mikhael et al.   BRITISH JOURNAL OF HAEMATOLOGY

Bendamustine (Treanda) Displays a Distinct Pattern of Cytotoxicity and Unique Mechanistic Features Compared with Other Alkylating Agents

(2008) L. M. Leoni et al.   CLINICAL CANCER RESEARCH

The combination of bortezomib, melphalan, dexamethasone and intermittent thalidomide is an effective regimen for relapsed/refractory myeloma and is associated with improvement of abnormal bone metabolism and angiogenesis

(2008) E Terpos et al.   LEUKEMIA